Study year | P* | |||||
---|---|---|---|---|---|---|
2002 | 2004 | 2006 | 2008 | Total 2002-2008 | ||
AT | ||||||
< 5 FEART without NRO | 56 (2.3%) | 47 (2.0%) | 43 (1.8%) | 44 (2.0%) | 190 (2.0%) | 0.539 |
< 5 FEART with NRO | 855 (34.5%) | 955 (41.3%) | 914 (37.5%) | 809 (36.1%) | 3533 (37.3%) | 1 |
≥ 5 FEART without NRO | 344 (13.9%) | 309 (13.4%) | 268 (11.0%) | 235 (10.5%) | 1156 (12.2%) | 0.010 |
≥ 5 FEART with NRO | 990 (40.0%) | 779 (33.7%) | 984 (40.4%) | 920 (41.0%) | 3673 (38.8%) | 0.637 |
GABHS infection | 233 (9.4%) | 223 (9.6%) | 227 (9.3%) | 234 (10.4%) | 917 (9.7%) | 0.553 |
Total AT | 2478 | 2313 | 2436 | 2242 | 9469 | 0.307 |
(100%) | (100%) | (100%) | (100%) | (100%) | ||
T | ||||||
< 5 FEART without NRO | 6 (4.3%) | 24 (10.9%) | 9 (4.8%) | 3 (1.8%) | 42 (5.9%) | 0.605 |
< 5 FEART with NRO | 9 (6.5%) | 25 (11.3%) | 23 (12.4%) | 20 (11.8%) | 77 (10.8%) | 0.132 |
≥ 5 FEART without NRO | 72 (52.2%) | 106 (48.0%) | 74 (39.8%) | 71 (42.0%) | 323 (45.2%) | 0.109 |
≥ 5 FEART with NRO | 40 (29.0%) | 46 (20.8%) | 58 (31.2%) | 65 (38.5%) | 209 (29.3%) | 0.317 |
GABHS infection | 11 (8.0%) | 20 (9.0%) | 22 (11.8%) | 10 (5.9%) | 63 (8.8%) | 0.845 |
Total T | 138 | 221 | 186 | 169 | 714 | 0.784 |
(100%) | (100%) | (100%) | (100%) | (100%) | ||
Total AT+T | 2616 (100%) | 2534 | 2622 | 2411 | 10183 | 0.309 |
(100%) | (100%) | (100%) | (100%) | (100%) | ||
A | ||||||
< 5 FEART without NRO | 285 (21.9%) | 237 (20.4%) | 293 (28.1%) | 265 (24.6%) | 1080 (23.5%) | 0.373 |
< 5 FEART with NRO | 379 (29.1%) | 282 (24.3%) | 254 (24.3%) | 277 (25.7%) | 1192 (26.0%) | 0.508 |
≥ 5 FEART without NRO | 25 (1.9%) | 17 (1.5%) | 9 (0.9%) | 13 (1.2%) | 64 (1.4%) | 0.225 |
≥ 5 FEART with NRO | 241 (18.5%) | 259 (22.3%) | 236 (22.6%) | 211 (19.6%) | 947 (20.6%) | 0.592 |
NRO | 373 (28.6%) | 367 (31.6%) | 252 (24.1%) | 312 (28.9%) | 1304 (28.4%) | 0.689 |
Total A | 1303 | 1162 | 1044 | 1078 | 4587 | 0.113 |
(100%) | (100%) | (100%) | (100%) | (100%) |